Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Cerus Corporation (CERS)

3.8199   -0.04 (-1.04%) 11-28 10:20
Open: 3.74 Pre. Close: 3.86
High: 3.875 Low: 3.78
Volume: 160,363 Market Cap: 678(M)

Technical analysis

as of: 2022-11-28 9:47:06 AM
Overall:       
Stoxline posted a STRONG SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 4.85     One year: 5.67
Support: Support1: 3.59    Support2: 3.25
Resistance: Resistance1: 4.15    Resistance2: 4.85
Pivot: 3.86
Moving Average: MA(5): 3.84     MA(20): 3.79
MA(100): 4.31     MA(250): 5
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 57.4     %D(3): 62.5
RSI: RSI(14): 49.9
52-week: High: 7.19  Low: 3.25
Average Vol(K): 3-Month: 1,236 (K)  10-Days: 705 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ CERS ] has closed above bottom band by 36.3%. Bollinger Bands are 34% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 3.91 - 3.93 3.93 - 3.95
Low: 3.78 - 3.8 3.8 - 3.83
Close: 3.82 - 3.85 3.85 - 3.89

Company Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

Headline News

Mon, 28 Nov 2022
CEC vows to improve electoral roll system - Pakistan Today

Mon, 28 Nov 2022
Hezbollah could use chlorine rockets as 'last resort' in future war - JNS.org

Sun, 27 Nov 2022
NK aims to have world’s strongest nuclear force - BusinessWorld Online

Mon, 21 Nov 2022
Cerus's Return On Capital Employed Overview - Cerus (NASDAQ:CERS) - Benzinga

Fri, 18 Nov 2022
Updating the Uniform Commercial Code for a Digital Age - Foley & Lardner LLP

Tue, 15 Nov 2022
BTIG Research Trims Cerus (NASDAQ:CERS) Target Price to $6.00 - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Devices
Shares Out. 177 (M)
Shares Float 156 (M)
% Held by Insiders 3.2 (%)
% Held by Institutions 81.1 (%)
Shares Short 6,640 (K)
Shares Short P.Month 7,580 (K)

Stock Financials

EPS -0.29
EPS Est Next Qtl -0.16
EPS Est This Year -0.64
EPS Est Next Year -0.48
Book Value (p.s.) 0.4
Profit Margin (%) -24.3
Operating Margin (%) -19.7
Return on Assets (ttm) -9
Return on Equity (ttm) -49.5
Qtrly Rev. Growth 9.5
Gross Profit (p.s.) 0.37
Sales Per Share 0.88
EBITDA (p.s.) -0.16
Qtrly Earnings Growth 0
Operating Cash Flow -25 (M)
Levered Free Cash Flow -2 (M)

Stock Valuations

PE Ratio -13.23
PEG Ratio 0
Price to Book value 9.25
Price to Sales 4.26
Price to Cash Flow -26.85

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.